These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 36233063)
21. LKB1 is a DNA damage response protein that regulates cellular sensitivity to PARP inhibitors. Wang YS; Chen J; Cui F; Wang H; Wang S; Hang W; Zeng Q; Quan CS; Zhai YX; Wang JW; Shen XF; Jian YP; Zhao RX; Werle KD; Cui R; Liang J; Li YL; Xu ZX Oncotarget; 2016 Nov; 7(45):73389-73401. PubMed ID: 27705915 [TBL] [Abstract][Full Text] [Related]
22. Alkylation DNA damage in combination with PARP inhibition results in formation of S-phase-dependent double-strand breaks. Heacock ML; Stefanick DF; Horton JK; Wilson SH DNA Repair (Amst); 2010 Aug; 9(8):929-36. PubMed ID: 20573551 [TBL] [Abstract][Full Text] [Related]
23. PLX038: A Long-Acting Topoisomerase I Inhibitor With Robust Antitumor Activity in ATM-Deficient Tumors and Potent Synergy With PARP Inhibitors. Thomas A; Fontaine SD; Diolaiti ME; Desai P; Kumar R; Takahashi N; Sciuto L; Nichols S; Ashworth A; Feng FY; Ashley GW; Nguyen M; Pommier Y; Santi DV Mol Cancer Ther; 2022 Nov; 21(11):1722-1728. PubMed ID: 35999657 [TBL] [Abstract][Full Text] [Related]
24. Rotavirus activates a noncanonical ATM-Chk2 branch of DNA damage response during infection to positively regulate viroplasm dynamics. Sarkar R; Patra U; Lo M; Mukherjee A; Biswas A; Chawla-Sarkar M Cell Microbiol; 2020 Mar; 22(3):e13149. PubMed ID: 31845505 [TBL] [Abstract][Full Text] [Related]
25. Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines. Kubota E; Williamson CT; Ye R; Elegbede A; Peterson L; Lees-Miller SP; Bebb DG Cell Cycle; 2014; 13(13):2129-37. PubMed ID: 24841718 [TBL] [Abstract][Full Text] [Related]
26. RING1 and YY1 binding protein suppresses breast cancer growth and metastasis. Zhou H; Li J; Zhang Z; Ye R; Shao N; Cheang T; Wang S Int J Oncol; 2016 Dec; 49(6):2442-2452. PubMed ID: 27748911 [TBL] [Abstract][Full Text] [Related]
27. New Synthetic Lethality Re-Sensitizing Platinum-Refractory Cancer Cells to Cisplatin In Vitro: The Rationale to Co-Use PARP and ATM Inhibitors. Folk WP; Kumari A; Iwasaki T; Cassimere EK; Pyndiah S; Martin E; Homlar K; Sakamuro D Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948122 [TBL] [Abstract][Full Text] [Related]
28. Polycomb protein RYBP activates transcription factor Henry S; Kokity L; Pirity MK Open Biol; 2023 Feb; 13(2):220305. PubMed ID: 36751888 [TBL] [Abstract][Full Text] [Related]
29. Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor. Takagi M; Yoshida M; Nemoto Y; Tamaichi H; Tsuchida R; Seki M; Uryu K; Nishii R; Miyamoto S; Saito M; Hanada R; Kaneko H; Miyano S; Kataoka K; Yoshida K; Ohira M; Hayashi Y; Nakagawara A; Ogawa S; Mizutani S; Takita J J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059438 [TBL] [Abstract][Full Text] [Related]
30. Cancer Cells Haploinsufficient for ATM Are Sensitized to PARP Inhibitors by D'Ambrosio C; Erriquez J; Capellero S; Cignetto S; Alvaro M; Ciamporcero E; Di Renzo MF; Perera T; Valabrega G; Olivero M Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628590 [TBL] [Abstract][Full Text] [Related]
31. Androgen Receptor Inhibitor Enhances the Antitumor Effect of PARP Inhibitor in Breast Cancer Cells by Modulating DNA Damage Response. Min A; Jang H; Kim S; Lee KH; Kim DK; Suh KJ; Yang Y; Elvin P; O'Connor MJ; Im SA Mol Cancer Ther; 2018 Dec; 17(12):2507-2518. PubMed ID: 30232143 [TBL] [Abstract][Full Text] [Related]
32. MET inhibition enhances PARP inhibitor efficacy in castration-resistant prostate cancer by suppressing the ATM/ATR and PI3K/AKT pathways. Zhou S; Dai Z; Wang L; Gao X; Yang L; Wang Z; Wang Q; Liu Z J Cell Mol Med; 2021 Dec; 25(24):11157-11169. PubMed ID: 34761497 [TBL] [Abstract][Full Text] [Related]
33. An Interaction with PARP-1 and Inhibition of Parylation Contribute to Attenuation of DNA Damage Signaling by the Adenovirus E4orf4 Protein. Nebenzahl-Sharon K; Sharf R; Amer J; Shalata H; Khoury-Haddad H; Sohn SY; Ayoub N; Hearing P; Kleinberger T J Virol; 2019 Oct; 93(19):. PubMed ID: 31315986 [TBL] [Abstract][Full Text] [Related]
34. Regulation of transcription patterns, poly(ADP-ribose), and RNA-DNA hybrids by the ATM protein kinase. Woolley PR; Wen X; Conway OM; Ender NA; Lee JH; Paull TT Cell Rep; 2024 Mar; 43(3):113896. PubMed ID: 38442018 [TBL] [Abstract][Full Text] [Related]
35. Interactions Between Ataxia Telangiectasia Mutated Kinase Inhibition, Poly(ADP-ribose) Polymerase-1 Inhibition and BRCA1 Status in Breast Cancer Cells. Węsierska-Gądek J; Heinzl S J Cancer Prev; 2014 Jun; 19(2):125-36. PubMed ID: 25337581 [TBL] [Abstract][Full Text] [Related]
36. Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53. Williamson CT; Kubota E; Hamill JD; Klimowicz A; Ye R; Muzik H; Dean M; Tu L; Gilley D; Magliocco AM; McKay BC; Bebb DG; Lees-Miller SP EMBO Mol Med; 2012 Jun; 4(6):515-27. PubMed ID: 22416035 [TBL] [Abstract][Full Text] [Related]
37. Resistance to DNA-damaging treatment in non-small cell lung cancer tumor-initiating cells involves reduced DNA-PK/ATM activation and diminished cell cycle arrest. Lundholm L; Hååg P; Zong D; Juntti T; Mörk B; Lewensohn R; Viktorsson K Cell Death Dis; 2013 Jan; 4(1):e478. PubMed ID: 23370278 [TBL] [Abstract][Full Text] [Related]
38. RYBP, a new repressor protein that interacts with components of the mammalian Polycomb complex, and with the transcription factor YY1. García E; Marcos-Gutiérrez C; del Mar Lorente M; Moreno JC; Vidal M EMBO J; 1999 Jun; 18(12):3404-18. PubMed ID: 10369680 [TBL] [Abstract][Full Text] [Related]